Description
Cultrex®StemCellQualifiedHumanFibronectin,Pathclear®ispurifiedfromhumanplasmaandisPathclear®certifiedtobefreeofcommonpathogens.Fibronectinisanextracellularmatrixproteinthatisfoundabundantlyinbloodandconnectivetissues.Thesematricesareassociatedwiththeepithelialtomesenchymaltransitionofmetastaticcells,includingtumorcellswithstemcell-likeproperties.Fibronectinperformsessentialfunctionsincollagenfibrillogenesis,aseitherageneralcelladhesionmoleculeoramodulatorinbindingbetweencellsurfacesandtheextracellularmatrix.Fibronectinmatrixassemblyisessentialfornormalvertebratedevelopmentandapparentlycontributestothegenerationoftumormetastasesbysupportingtheestablishmentandpersistenceofpre-metastaticniches.Fibronectinissecretedasadisulfide-linkeddimerof230-270kDa,comprisedofthreetypesofrepeatingmodulesthatmediateinteractionswithextracellularmatrixcomponents(includingfibronectinitself),andcellsviaintegrinsandotherfibronectinreceptors.Thus,fibronectincanbeusedforcoatingtissueculturesurfacesorasamediumadditivetopromotecelladhesionandproliferation;itis0.2μmsterilefiltered.
Cultrex®StemCellQualifiedHumanFibronectin,Pathclear®isapurifiedplasmaextracellularmatrix proteinthathasbeendeveloped,producedandqualifiedspecifically toprovideafunctionallydefinedandeffectivefeeder-freesurfacefortheattachmentandmaintenanceofembryonicstemcellsinapluripotentstate
Qualitycontrolspecifications:
- PathClear®–testednegativeforeighthumanpathogenicvirusesincludingHepatitisA,BandC,HIV1and2,Hantaan,Seoul,andSinNombrebyPCR.
- Nobacterialorfungalgrowthdetectedafterincubationat37°Cfor14daysfollowingUSPsterilitytestingguidelines.
- Endotoxinconcentration≤20EU/mlbyLimulusAmoebocyteLysate(LAL)assay.
- Proteinconcentrationof1mg/ml.
- NomycoplasmacontaminationdetectedbyPCR.
- Providedin100mMCAPS,150mMNaCl,1mMCaCI2,pH11.5.
- Purity ≥90%(SDS-PAGE).
- BIOLOGicalactivitydeterminedforeachlot:
- PromotestheattachmentofhumaniPSCs.
- EffectivelymaintainshumaniPSCsinapluripotentstateinafeeder-freeculture.
SafetyStatement:
AlthoughCultrex®StemCellQualifiedHumanFibronectin,PathClear®hasbeentestedforthevirusesaboveitcontainshumansourcematerialandthereforeshouldbetreatedaspotentiallyinfectiousandhandledattheBiologicalSafetyLevel2tominimizeexposure.
Trevigen公司位于美国马里兰州的高科技走廊，是一家有12年历史、成长迅速的生物技术公司，其产品和技术的发展方向主要在癌症研究领域，重点强调细胞凋亡、DNA损伤和修复，以及癌症细胞功能和行为。Trevigen品牌的分销商遍及北美，欧洲和环太平洋地区。关于DNA的损伤分析技术的研究，Trevigen获得美国国立卫生研究院（NIH）的SBIR项目资助。
